Published • loading... • Updated
US FDA Approves Lilly’s Breast Cancer Drug Combo
The all-oral regimen doubled median progression-free survival to 11.1 months in a 159-patient late-stage study, Lilly said.
Summary by WTVB
8 Articles
8 Articles
Eli Lilly Stock Ends Flat After FDA Expands Inluriyo–Verzenio Use
Eli Lilly won full U.S. Food and Drug Administration approval on Friday for Inluriyo used with Verzenio in a defined group of patients with advanced breast cancer. The stock barely moved: Lilly shares closed at $1,152.93 on Sept. 18, up 49 cents, or 0.04%, from Thursday. That subdued finish is a useful measure of the…
Coverage Details
Total News Sources8
Leaning Left0Leaning Right3Center3Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
